Why the study?
Does losartan reduce the progression to ESRD and cardiovascular events in patients with type 2 diabetes mellitus and nephropathy?
Population
Patients with type 2 diabetes mellitus (T2DM) and hypertension or nephropathy
Design
Review
Authors
Loading...
Supports losartan consideration in T2DM nephropathy; leaves open need for updated RCTs versus contemporary therapies.
Does losartan reduce the progression to ESRD and cardiovascular events in patients with type 2 diabetes mellitus and nephropathy?
This review highlights that losartan is an effective treatment for reducing the progression of diabetic nephropathy and the risk of ESRD and cardiovascular events in patients with T2DM.
Brian Rayner (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: